|
|
Article: Spectrum Pharmaceuticals Announces That Sumatriptan Injection Litigation With GlaxoSmithKline(R) Has Been Dismissed Pursuant to the Settlement Agreement.
- Article from:
- PR Newswire
- Article date:
- December 21, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* Litigation dismissed after the 30-day review period passed with no comment from the Federal Trade Commission (FTC)
* Spectrum expects Sumatriptan Injection to launch in 2H 2008
* Spectrum received $5 million as a milestone payment from PAR earlier this month
* Spectrum to receive majority of profit from sales
IRVINE, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. announced today that patent litigation relating to sumatriptan injection, the generic version of GlaxoSmithKline's(R) Imitrex(R) Injection, has been dismissed by the United States District Court for the District of Delaware pursuant to the ...